The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Open accessAbstract
Capsid decoys enhance the efficacy of AAV vector transduction after systemic delivery in the presence of neutralizing antibodies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a capsid decoy strategy by Mingozzi et al. demonstrated that mixing gene therapy vectors with empty AAV2-based capsid particles with mutations that ablate primary cell receptor binding could enhance transduction of the gene therapy vector in the presence of low to moderate levels of neutralizing antibodies.76”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [76]
In the citing paper
“Interestingly, empty capsids were used as decoy for anti-AAV antibodies, and thus allowed for ef fi cient transduction of genomecontaining capsids and transgene expression in mice and NHPs (130).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [130]
In the citing paper
“To this end, mutation was introduced into the receptor binding site of capsid to generate an empty capsid mutant, which could not enter target cells but maintained the ability to absorb antibodies (130).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [130]
In the citing paper
“Remarkably, even in the presence of high NAb titer (1:3,000), addition of empty capsids achieved ~45% of transgene expression from the control group that did not receive IVIG.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [130]
In the citing paper
“Another approach consists of proteasome inhibitors, such as carfilzomib and bortezomib, limiting rAAV degradation and antibody presentation; and hydroxychloroquine, inhibiting viral particle recognition by TLR and cGAS [12,[133][134][135].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [133]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 26×
“The three animals dosed with vector formulated in empty capsids— 4001, 4002, and 6001 (all with detectable baseline NAbs; Table 1)— expressed hF.IX at higher levels than the vector only group, between ~300 and 450 ng/ml (Fig.”
BackgroundMethodInfluentialSelf-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“of AAV8 vectors for hepatocytes compared with AAV2 vectors (20) or the fact that the AAV8 vector carried a self-complementary genome, postulated to drive higher transgene expression levels (22, 25).”
BackgroundMethodClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“Recent work from several laboratories explored the use of alternate AAV serotypes (6, 36) or AAV capsid mutants that escape anti-AAV antibodies (37).”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 4×
“Moreover, crossreactivity of anti-AAV antibodies results in neutralization of a wide range of AAV serotypes (5), eliminating the obvious solution of switching AAV serotype.”
BackgroundInfluentialWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 2×
“However, with a prevalence of 30 to 60% in humans (5, 6), neutralizing antibodies (NAbs) to AAV constitute a major obstacle, and other studies have shown that these NAbs, even at relatively low titers, block gene transfer when vector is delivered through the vasculature (2, 7, 8).”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 3×
“Thus, although increasing the total capsid dose (empty particles and DNA-bearing vector particles) helps to evade anti-AAV humoral responses, it may increase the likelihood of triggering potentially harmful T cell responses against the AAV capsid (1, 2, 11).”
BackgroundSelf-citation
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citation
Metadata
- Authors
- Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., Howard, C., Tai, A., Podsakoff, G. M., Zhou, S., Basner-Tschakarjan, E., Wright, J. F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Department of Pediatrics and Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
- Corresponding author
- Mingozzi, Federico
- High, Katherine A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2013-07-17
- Volume
- 5
- Issue
- 194
- Pages
- 194ra92-194ra92
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4095828
- OpenAlex
- W2164545730
- Cited by
- 355
- References
- 44
- Citations by year
- 2026: 14 · 2025: 35 · 2024: 28 · 2023: 34 · 2022: 33 · 2021: 29 · 2020: 23 · 2019: 28 · 2018: 24 · 2017: 30 · 2016: 16 · 2015: 27 · 2014: 26 · 2013: 7
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL078810)
- National Center for Research Resources (G20RR030997)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus vectors, neutralizing antibodies, capsid mutants, antibody adsorption, systemic gene delivery, nonhuman primate model
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Capsid, Humans, Macaca mulatta, Male, Mice, Inbred C57BL, Mutation, Neutralization Tests, Gene Transfer Techniques, Mice, Immunity, Humoral, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys. https://app.cochat.ai/papers/10.1126/scitranslmed.3005795
- The paper
- Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., Howard, C., Tai, A., Podsakoff, G. M., Zhou, S., Basner-Tschakarjan, E., Wright, J. F., & High, K. A. (2013). Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3005795
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.